Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 43 Results

Title
Intervention Indication Therapeutic Area Year Actions
Cediranib with olaparib for previously treated platinum resistant recurrent ovarian cancer Cediranib (Recentin; AZD2171) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Ovarian cancer Female Reproductive Cancer 2021 View  |  Download
Cemiplimab for recurrent, persistent or metastatic cervical cancer – second line Cemiplimab (Libtayo; REGN2810) Cervical cancer Female Reproductive Cancer 2020 View  |  Download
Dostarlimab in addition to carboplatin and paclitaxel for recurrent or primary advanced endometrial cancer Carboplatin (Paraplatin) , Dostarlimab (TSR-042; Jemperli) , Paclitaxel (Taxol; paclitaxel albumin) Endometrial cancer Female Reproductive Cancer 2021 View  |  Download
Dostarlimab with chemotherapy and niraparib for treating advanced epithelial ovarian cancers – first line Chemotherapy , Dostarlimab (TSR-042; Jemperli) , Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate) Epithelial ovarian cancers Female Reproductive Cancer 2023 View  |  Download
Dostarlimab with paclitaxel and carboplatin for recurrent or primary advanced endometrial cancer Carboplatin (Paraplatin) , Dostarlimab (TSR-042; Jemperli) , Paclitaxel (Taxol; paclitaxel albumin) Endometrial cancer Female Reproductive Cancer 2023 View  |  Download
Durvalumab add-on therapy for previously untreated locally advanced cervical cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Cervical cancer Female Reproductive Cancer 2022 View  |  Download
Durvalumab with bevacizumab and chemotherapy for treating advanced ovarian cancers Bevacizumab (Avastin; R 435; RG 405; RG 435) , Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Ovarian cancer Female Reproductive Cancer 2023 View  |  Download
Durvalumab with carboplatin and paclitaxel with or without olaparib for newly diagnosed advanced or reccurent endometrial cancer Carboplatin (Paraplatin) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Paclitaxel (Taxol; paclitaxel albumin) Endometrial cancer Female Reproductive Cancer 2023 View  |  Download
Lenvatinib in combination with pembrolizumab for advanced endometrial cancer – second line Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Endometrial cancer Female Reproductive Cancer 2020 View  |  Download
Lenvatinib in combination with Pembrolizumab for advanced or recurrent endometrial cancer - First Line Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Endometrial cancer Female Reproductive Cancer 2021 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications